文献速递免疫规划

鼻内纳米颗粒疫苗可诱导针对结核分枝杆菌的保护性免疫

An intranasal nanoparticle vaccine elicits protective immunity against Mycobacterium tuberculosis.
PubMed 文献 · Vaccine · 2024-05-03

本研究以脂质体包裹的STING通路内源性激活剂cGAMP(NanoSTING)为黏膜佐剂,与H1抗原(Ag85b与ESAT-6融合蛋白)制成疫苗,经鼻内免疫动物后诱导肺部T细胞多重应答,在气溶胶攻击结核分枝杆菌Erdman株时提供的保护与皮下接种活减毒牛分枝杆菌疫苗株BCG相当。

要点

  • 鼻内NanoSTING-H1疫苗诱导肺部CXCR3+KLRG1-组织驻留T细胞、分泌IFNγ的CD4+T细胞和分泌IL17的CD4+T细胞。
  • 气溶胶攻击结核分枝杆菌Erdman株后,鼻内NanoSTING-H1提供的保护与皮下接种BCG相当。
  • NanoSTING佐剂蛋白疫苗可诱导多因素黏膜免疫应答以抵抗结核分枝杆菌感染。

核心结论

  • NanoSTING佐剂蛋白疫苗可诱导多因素免疫应答,保护动物免受结核分枝杆菌感染。

研究设计与样本

  • 研究以脂质体包裹的cGAMP(NanoSTING)为黏膜佐剂,与H1抗原(Ag85b与ESAT-6融合蛋白)制成疫苗,经鼻内免疫动物,并以气溶胶攻击结核分枝杆菌Erdman株评估保护效果。

主要发现

  • 鼻内免疫NanoSTING-H1在疫苗接种动物肺部诱导强T细胞应答,包括CXCR3+KLRG1-肺组织驻留T细胞、分泌IFNγ的CD4+T细胞和分泌IL17的CD4+T细胞。
  • 气溶胶攻击结核分枝杆菌Erdman株后,鼻内NanoSTING-H1提供的保护与皮下接种活减毒牛分枝杆菌疫苗株BCG相当。

关键数值与推荐

  • 鼻内NanoSTING-H1诱导的肺部T细胞应答包括CXCR3+KLRG1-肺组织驻留T细胞、分泌IFNγ的CD4+T细胞和分泌IL17的CD4+T细胞。
  • 气溶胶攻击结核分枝杆菌Erdman株后,鼻内NanoSTING-H1提供的保护与皮下接种BCG相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mucosal vaccines have the potential to elicit protective immune responses at the point of entry of respiratory pathogens, thus preventing even the initial seed infection. Unlike licensed injectable vaccines, mucosal vaccines comprising protein subunits are only in development. One of the primary challenges associated with mucosal vaccines has been identifying and characterizing safe yet effective mucosal adjuvants that can effectively prime multi-factorial mucosal immunity. In this study, we tested NanoSTING, a liposomal formulation of the endogenous activator of the stimulator of interferon genes (STING) pathway, cyclic guanosine adenosine monophosphate (cGAMP), as a mucosal adjuvant. We formulated a vaccine based on the H1 antigen (fusion protein of Ag85b and ESAT-6) adjuvanted with NanoSTING. Intranasal immunization of NanoSTING-H1 elicited a strong T-cell response in the lung of vaccinated animals characterized by (a) CXCR3+ KLRG1- lung resident T cells that are known to be essential for controlling bacterial infection, (b) IFNγ-secreting CD4+ T cells which is necessary for intracellular bactericidal activity, and (c) IL17-secreting CD4+ T cells that can confer protective immunity against multiple clinically relevant strains of Mtb. Upon challenge with aerosolized Mycobacterium tuberculosis Erdman strain, intranasal NanoSTING-H1 provides protection comparable to subcutaneous administration of the live attenuated Mycobacterium bovis vaccine strain Bacille-Calmette-Guérin (BCG). Our results indicate that NanoSTING adjuvanted protein vaccines can elicit a multi-factorial immune response that protects from infection by M. tuberculosis.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sefat KMSR, Kumar M, Kehl S, et al. An intranasal nanoparticle vaccine elicits protective immunity against Mycobacterium tuberculosis. Vaccine. 2024. PMID: 38704256. doi:10.1016/j.vaccine.2024.04.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。